OPENSCREEN-GR

OPENSCREEN-GR integrates high-capacity screening platforms throughout Greece, which jointly used a rationally selected collection, comprising up to 60000 commercial and proprietary compounds collected from Greek chemists.  OPENSCREEN-GR offers to researchers from academic institutions, SME’s and industrial organizations open access to its shared resources. 

OPENSCREEN-GR will collaboratively develop novel molecular tool compounds with external use from various disciplines of the life sciences.

BRFAA’s role is to provide nationwide access to:

• the metabolic stability and pharmacokinetic studies of the bioactive compounds that stem from the program (Dr Constantin Tamvakopoulos, Tamvakopoulos Lab)
• the assessment of the activity and toxicity of lead compounds using zebra fish models (Dr Dimitris Beis, Beis Lab, www.zebrafish.gr)
• Computer-aided drug design and in silico studies (Dr Zoe Cournia, Cournia Lab, www.drugdesign.gr).

Through its participation in the OPENSCREEN-GR: BRFAA will be actively linked to the national research community and interconnected production units and will have a key role in national initiatives and future funding efforts in the area of ​​discovery of drugs. BRFAA will benefit from a significant enhancement in its existing infrastructures (new instrumentation and personnel).  Importantly, through its participation in OPENSCREEN-GR, BRFAA will benefit through the interconnection of OPENSCREEN-GR with the corresponding OPENSCREEN-EU ERIC

We acknowledge support of this work by the project “OPENSCREEN-GR.” (MIS 5002691.) which is implemented under the Action “Reinforcement of the Research and Innovation Infrastructure”, funded by the Operational Programme "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund).